> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Stereotaxis Pursues Backup Catheter Supply As Shortages Block $1.9 Million In Orders
- URL: https://www.bullished.co/stereotaxis-pursues-backup-catheter-supply-as-shortages-block-1-9-million-in-orders-e7bf5582/
- Published: 2026-11-10T22:31:44.000Z
- Updated: 2026-11-10T22:31:44.000Z
- Description: Europe's switch to alternative catheters frees MAGIC supplies for U.S. customers, but production still falls short.
- Author: Matteo Parrino
- Tags: Earnings, STXS, Industry: Healthcare

[Stereotaxis](https://www.bullished.co/tag/stxs/), which develops surgical robots for minimally invasive procedures inside blood vessels, is pursuing backup catheter production after shortages left approximately [$1.9 million](https://www.sec.gov/Archives/edgar/data/0001289340/000149315226050957/ex99-1.htm?ref=bullished.co) in disposable orders unfilled entering the fourth quarter, according to its results release. On Tuesday's earnings call, Chairman and Chief Executive Officer David Fischel said production remained insufficient even for U.S. customers despite shifting European hospitals to alternatives.

## Europe Switches, U.S. Supply Stalls

Fischel said Osipka, the company's German contract manufacturer, had “grossly underperformed their own expectations.” MAGIC shipments failed to improve between the second and third quarters, with production hampered by difficulties increasing manufacturing yields and hiring staff capable of producing the catheters successfully.

Stereotaxis previously targeted 500 catheters a month to meet procedure needs across its installed robots worldwide. Current output falls short of U.S. needs alone, where MAGIC is the only available catheter for customers.

Europe has two alternatives that Stereotaxis sells through exclusive distribution agreements with industry partners. The company began directing European orders toward those products during the summer, reserving limited MAGIC output for the United States.

The shortages complicate hospitals' transition away from Johnson & Johnson's catheters and mapping systems toward Stereotaxis' own portfolio. Fischel described a hospital-by-hospital process: some transitions have been smooth, while others require help with administrative hurdles and new technology.

## Backup Production Meets Guarded Answers

Asked by an analyst how Stereotaxis would fix the shortage, Fischel pointed to internal capabilities and investments made over the last couple years. But he kept the production arrangements deliberately broad: “I want to still talk about things somewhat vaguely,” he said, citing the company's business and relationships with other parties.

Fischel expects regulatory decisions in early 2027 to enable redundant supply sufficient for U.S. demand, with the potential to serve Europe as well. Stereotaxis continues working with Osipka to improve output.

For the fourth quarter, Fischel expects roughly half, or slightly more, of the opening disposable backlog to be filled. He expects Europe’s alternative catheters to help lift recurring revenue to a new high even without improved MAGIC shipments, but remaining U.S. orders will stay constrained unless production increases.

## $12 Million Funds The Profitability Bet

Stereotaxis closed an initial $12 million financing through convertible notes—debt that can become shares—with another $12 million available at its option after regulatory milestones. Fischel said the additional funding depends on a milestone addressing MAGIC supply and that he believes the financing can carry the company to profitability within the next year.

The notes' conversion price is 30% above the recent stock price, Fischel said, with interest payable at maturity in three years. Including the initial proceeds, cash would total $16 million, compared with $4 million at September 30; the optional draw brings total funding availability to $28 million.

Third-quarter revenue [rose 20%](https://www.sec.gov/Archives/edgar/data/0001289340/000149315226050957/ex99-1.htm?ref=bullished.co) from a year earlier to $8.9 million. Recurring revenue reached $5.9 million, up 6% year over year but down 4% from the second quarter. Fischel said robotic-catheter revenue itself grew more than 20% from the prior quarter and more than 400% year over year, despite the supply problems.

System sales rose 60% to $3 million, helped by initial GenesisX revenue in the United States, Genesis revenue in China and Synchrony digital operating-room sales. Management expects more consistent capital sales alongside recurring-sales growth.

The quarter consumed $6.5 million in cash: $2.6 million for the core business and $3.9 million in Robocath acquisition payments. Management expects adjusted quarterly operating expenses, excluding non-cash and one-time items, of about $8 million.

Stereotaxis is investing in backup inventory now so it can fill the remaining backlog within days of regulatory approval, Fischel said.

Learn

- [How To Read An Earnings Call Transcript: Start With Guidance, Then Find What's Missing →](https://www.bullished.co/learn/how-to-read-an-earnings-call/)  
How to read an earnings call transcript: check guidance first, look for dropped metrics, compare growth with last quarter, and watch hedged wording.

### Sources

- [Stereotaxis results release (Form 8-K, EX-99.1)](https://www.sec.gov/Archives/edgar/data/0001289340/000149315226050957/ex99-1.htm?ref=bullished.co) — SEC EDGAR
- [Stereotaxis Reports 2026 Third Quarter Financial Results &](https://www.globenewswire.com/news-release/2026/11/10/3400189/0/en/stereotaxis-reports-2026-third-quarter-financial-results-business-updates.html?ref=bullished.co) — globenewswire.com
- [Stereotaxis Announces Convertible Note Financing of Up To](https://www.globenewswire.com/news-release/2026/11/10/3400180/0/en/stereotaxis-announces-convertible-note-financing-of-up-to-24-million.html?ref=bullished.co) — globenewswire.com

### More on Stereotaxis

- [Stereotaxis Sales Rise 20% With New Robot Revenue, But Catheter Shortages Limit Procedures](https://www.bullished.co/stereotaxis-sales-rise-20-with-new-robot-revenue-but-catheter-shortages-limit-procedures-6a65c95f/)

[All Stereotaxis (STXS) coverage →](https://www.bullished.co/tag/stxs/)